AQbD enabled optimization of RP-HPLC method for the estimation of pioglitazone and vildagliptin and its forced degradation studies
Background: Diabetes mellitus is a metabolic disorder that is managed with combination therapy. Pioglitazone improves insulin sensitivity by activating PPAR-γ, whereas vildagliptin increases incretin activity by inhibiting DPP-4. Their fixed-dose combination requires reliable analytical methods for...
Gardado en:
| Principais autores: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Creative Pharma Assent
2026-05-01
|
| Series: | Journal of Applied Pharmaceutical Research |
| Assuntos: | |
| Acceso en liña: | https://japtronline.com/index.php/joapr/article/view/1856 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|